Theratechnologies' Initial Efficacy Data From Ovarian Cancer Drug Trial Shows Encouraging Results

(RTTNews) - Theratechnologies Inc. (THTX), Monday, announced encouraging preliminary tolerability and efficacy data from part 3 of its ongoing Phase 1b trial, evaluating sudocetaxel zendusortide in patients with advanced ovarian cancer.

The study, involving 13 participants, was divided into two arms - A and B. Both the arms had a treatment schedule of three weeks on and one week off, repeated every 28 days.

In Arm A, participants received a 1.75-mg/kg/week dose of sudocetaxel zendusortide, whereas Arm B participants received a 2.5-mg/kg/week dose on a weekly infusion.

According to the study findings, no dose-limiting toxicities were observed in either arm.

While there were no responses observed in the five Arm A participants, three of the six patients enrolled in Arm B experienced significant reductions in the CA-125 ovarian tumor marker and tumor shrinkage, with one patient achieving a complete resolution of a liver lesion, the company noted.

Based on the findings, the Medical Review Committee has unanimously recommended continued evaluation and exploration of higher doses.

Currently, Theratechnologies's stock is trading at $1.49, up 4.93 percent on the Nasdaq.